MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use

(2011) Zahra Hanaizi et al.   EUROPEAN JOURNAL OF CANCER

Hyponatremia associated with Ipilimumab-induced hypophysitis

(2011) Zachary R. Barnard et al.   MEDICAL ONCOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab-Induced Hypophysitis: MR Imaging Findings

(2009) K.J. Carpenter et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Ipilimumab: controversies in its development, utility and autoimmune adverse events

(2009) Jeffrey Weber   CANCER IMMUNOLOGY IMMUNOTHERAPY

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

(2009) Troy Dillard et al.   Pituitary